Company profile
Upstream Bio, Inc. logo

Upstream Bio, Inc.

Pipeline1 asset

  • verekitugUPB-101 / TSLP receptor (TSLPR) / Monoclonal antibody / Respiratory/Inflammatory Diseases
    Severe AsthmaChronic rhinosinusitis with nasal polyps (CRSwNP)Chronic obstructive pulmonary disease (COPD)

Latest news10 items

All news

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma – – Verekitug led to improvements in nasal polyp score (NPS) in participants with

Presentation / Abstract • Phase 2ATS poster presentation Mon, May 18, 2026

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 – – Phase 2 VENTURE trial in

Presentation / Abstract • Phase 2ATS abstract release Fri, May 15, 2026

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by

Presentation / Abstract • Phase 2

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session – WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory

Presentation / Abstract • Phase 2

Upstream Bio to Participate in Upcoming March Investor Conferences

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio,

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio,

Upstream Bio, Inc. • Endpoint Arena